Myocardial Safety Following COVID-19 Vaccination

Abstract

Abstract Background and Aim Vaccination is a well-established part of preventive and public health medicine, but is not without risk. COVID-19 vaccination frequently leads to minor side-effects, for example pain, swelling and redness at the site of injection, and systemic symptoms of fatigue, headache, muscle pain, chills and fever; side effects after the second dose may be more intense than the first dose. Among the vaccines, more serious side effects have been reported, including myocarditis. This study was aimed to detect any evidence of myocardial damage after COVID-19 vaccination. Subjects and methods We selected 150 subjects (both sexes) randomized into two groups as 75 patients who are fully vaccinated with AstraZeneca vaccine (two doses) the study was conducted at least after two weeks from the second dose of the vaccine and 75 patients who are not vaccinated. Results This study was carried on 150 patients, 52 (34.7%) of whom were females, and 98 (65.3%) were males. The mean age of the studied group was (34 years old). The LVEDV (indexed) mean of 45.08 ml/m2 in the cases group and 43.8 ml/m2 in the control group. The EF mean of 63.2% in the cases group and 62.9% in the control group. And the GLS median of -19% in the cases group and -19% in the control group. Conclusion COVID-19 vaccination has no evidence association of any myocardial damage. Nevertheless, the advantages of these vaccines for ending the pandemic and/or decreasing the mortality rate outweigh any risk for the rare cardiovascular complications.